Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics


Iovance Biotherapeutics, Inc. (IOVA): $7.02

-8.10 (-53.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IOVA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IOVA Stock Price Chart Interactive Chart >

Price chart for IOVA

IOVA Price/Volume Stats

Current price $7.02 52-week high $28.00
Prev. close $15.12 52-week low $6.75
Day low $6.75 Volume 36,758,801
Day high $7.91 Avg. volume 2,501,119
50-day MA $15.69 Dividend yield N/A
200-day MA $18.92 Market Cap 1.10B

Iovance Biotherapeutics, Inc. (IOVA) Company Bio


Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.


IOVA Latest News Stream


Event/Time News Detail
Loading, please wait...

IOVA Latest Social Stream


Loading social stream, please wait...

View Full IOVA Social Stream

Latest IOVA News From Around the Web

Below are the latest news stories about Iovance Biotherapeutics Inc that investors may wish to consider to help them evaluate IOVA as an investment opportunity.

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

Expanding TIL Platform in Multiple Solid Tumors and Treatment SettingsSAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quarter and full year 2021 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer o

Yahoo | February 24, 2022

Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022

SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

GlobeNewswire | February 11, 2022

AlloVir: A Comparative Study Of Its Manufacturing Process

I covered AlloVir (ALVR) early last year, and like so many things in 2021, the stock hasn’t done well. AlloVir is Marker’s (MRKR) sister company, and uses the same technology in infectious diseases instead of Marker’s cancer focus. A number of other companies - SQZ Biotechnologies (SQZ), Iovance (IOVA), and...

Avisol Capital Partners on Seeking Alpha | February 7, 2022

Did The Smart Money Get Iovance Biotherapeutics, Inc. (IOVA) Right?

Technology stocks had a lousy start to 2022. QQQ lost 9% of its value in January. Pandemic winners are getting crushed while energy stocks are surging.

Insider Monkey | February 6, 2022

Carnegie Capital Asset Management, LLC Buys Coinbase Global Inc, GXO Logistics Inc, Upstart ...

Beachwood, OH, based Investment company Carnegie Capital Asset Management, LLC (Current Portfolio) buys Coinbase Global Inc, GXO Logistics Inc, Upstart Holdings Inc, FuboTV Inc, QuantumScape Corp, sells , Guardant Health Inc, Verizon Communications Inc, Arista Networks Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Carnegie Capital Asset Management, LLC.

Yahoo | January 21, 2022

Read More 'IOVA' Stories Here

IOVA Price Returns

1-mo -53.66%
3-mo -55.20%
6-mo -62.50%
1-year -62.20%
3-year -60.63%
5-year 36.31%
YTD -63.23%
2021 -58.86%
2020 67.63%
2019 212.77%
2018 10.63%
2017 15.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5599 seconds.